News

Health Affairs1dOpinion
Congress Should Remove The Rare Disease Carve-Out From Medicare Drug Price Negotiation, Not Expand It
Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...
The Pharma Letter2d
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst
US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...
Targeted Oncology2d
CARTITUDE-4 Study: Cilta-cel Benefits High-Risk Myeloma & EMD Subgroups
Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...
The American Journal of Managed Care3d
Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS
Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...
Cigna files antitrust case against Bristol Myers over Pomalyst sales
Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition ...
Cigna sues Bristol Myers for alleged monopoly over blockbuster multiple myeloma drug
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...